Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Baird analyst Joel Beatty maintains Cogent Biosciences (NASDAQ:COGT) with a Neutral and raises the price target from $8 to $10.
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and lowers the price targ...
Based on strong global patient interest, a total of 413 patients were enrolled in the study. In addition, Cogent recently compl...
JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and lowers the price target from ...
Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of ...
Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $18 price target.
Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defin...
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $19 price ...
